Active ingredients at their site of action
Personalized implants that release drugs exactly where they are supposed to act
News
We are starting 2026 with the achievement of an official manufacturing approval for our round window niche implant (RNI)!
Why is this so important? Our RNIs fall within the scope of highly regulated medicinal products. Only with the manufacturing license can we test our RNIs in an initial clinical study.
Wow! 🏆
On August 27, 2024, we had the opportunity to pitch our project alongside eight other initiatives in front of a distinguished jury at the HZI Braunschweig. Later that day, we received the fantastic news. With this funding, we can take another important step in the development of our implant.
The technology for the production of drug-releasing implants enables, among other things, the treatment of patients with ear canal stenosis. A television team from NDR (Norddeutscher Rundfunk - North german broadcasting) broadcasted a report on these external ear canal implants, which were printed using our technology, on December 12, 2023.
You'll find other news here
Round window
niche implant
(RNI)
for the treatment
of hearing loss
Round window niche implant (RNI) for the treatment of hearing loss
To date, no medications are approved for the treatment of the various forms of hearing loss. One reason for this is that drugs have to be applied locally to the inner ear to have a beneficial effect. But until today, there is no approved device bringing the drug into the inner ear. Bacta Implants technology enables the fabrication of individualized implants tailored to the patient´s round window niche, facilitating safe and minimally invasive delivery of inner ear therapies.
Our first product will be the Round Window Niche Implant (RNI), which delivers the drug dexamethasone, approved for decades, into the inner ear to treat sudden sensorineural hearing loss (ISSHL).
Further information
Are you interested in advanced therapeutic options for sudden idiopathic sensorineural hearing loss?
You need to deliver an active substance, but systemic application isnt effective enough?
We are a start-up company from the Hannover Medical School and open for investors.